White subjects with AO (waist circumference >94 cm for men and >80 cm for women) 2 aged 40 to 65 years and age-and sex-matched healthy
O besity has reached worldwide epidemic proportions. The risk of developing chronic heart failure (HF) is higher in patients who are obese and, more specifically so, subjects with abdominal obesity (AO) 1, 2 independently of other cardiovascular risk factors such as hypertension and diabetes mellitus. In an effort to help healthcare providers with the early identification of patients who are at risk for developing HF, the American College of Cardiology/American Heart Association 2005 classification 3 of chronic HF has insisted on the early asymptomatic stages. However, the mechanisms underlying the transition from risk factors (stage A: patients at risk for HF but without structural heart disease or symptoms of HF) to early asymptomatic cardiac and vascular structural (stage B: patients with structural heart disease but without signs or symptoms of HF) and functional changes are still poorly understood. 4 At least in hypertension, early cardiac and vascular remodeling is the result of pressure overload and interstitial fibrosis. 5 Our group has also reported that early changes in extracellular matrix biomarkers could be detected not only in patients with diabetes mellitus and hypertension 6 but also in obese and otherwise healthy subjects. 7 Whether subjects with AO develop adverse cardiac and vascular remodeling has not been investigated to date. The aim of the present study is to assess whether changes in cardiac and arterial remodeling can be detected at an early stage in subjects with AO and otherwise healthy and normotensive and to investigate the contribution of blood pressure (BP) and myocardial fibrosis turnover to such potential changes.
Hypertension
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volunteers without AO and body mass index <25 kg/m 2 were consecutively recruited. Subjects with diabetes mellitus (taking antidiabetic agents or screening visit fasting glucose >7 mmol/L), hypertension (on antihypertensive therapy or BP >140/90 mm Hg at the screening visit or the enrollment visit), body mass index >40 kg/m 2 , history of cardiovascular, or endocrine, inflammatory, or malignant diseases were excluded. The study complied with the Declaration of Helsinki. 8 Written informed consent was obtained from all subjects. Local Ethics Committee approved the study. No clinical trials.gov number was assigned to this study because it started before July 1, 2005.
Metabolic Phenotyping
Blood was sampled between 8 and 10 am after maintaining a supine position for 30 minutes and the following were assessed: fasting glucose, oral glucose tolerance test (to exclude patients with diabetes mellitus), glycohemoglobin, serum creatinine (estimated glomerular filtration rate by the MDRD [Modification of the Diet in Renal Disease] formula), 9 ultrasensitive C-reactive protein, alanine aminotransferase, lipid profile, leptin, and adiponectin (R&D Systems, Minneapolis, MN). Body composition was estimated from the attenuation of radiographs pulsed synchronously between 40 and 100 keV using a LUNARs DPX-IQ system (LUNARs Corporation, Madison, WI).
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Cardiac Phenotyping
Left ventricular (LV) diastolic function was assessed with transthoracic Doppler echocardiography (HDI 5000), with measurements of peak E wave, peak A wave, E/A ratio, deceleration time of E wave, together with Doppler tissue imaging of the lateral part of mitral annulus: peak E′ wave, peak A′ wave, and E/E′ ratio. The European Society of Echocardiography guidelines were used to grade diastolic dysfunction, 11 diagnosed if E′ was <10 cm/s. Cardiac MRI was performed on a 1.5-T magnet (Signa Excite; GE Medical Systems, Milwaukee, WI) equipped with an 8-element phased-array surface coil. A steady-state free precession pulse sequence was used to assess LV function in contiguous short-axis planes, as previously described in detail elsewhere. 12 LV end-diastolic volume, LV end-systolic volume, LV stroke volume, LV ejection fraction (EF), and LV mass were determined on the contiguous short-axis slices using dedicated software (MASS, Medis, The Netherlands). LV mass was determined at end diastole, and papillary muscles and trabeculations were excluded for LV mass and LV volume measurements. 12 Different scales were used to normalize LV mass: height 1.7 , 13 height 2.7 , 14 and fat-free mass. 15 Cardiac remodeling index (CRI), indicating concentric LV remodeling, is represented by the ratio of LV mass/LV end-diastolic volume. 16 LV hypertrophy, assessed by MRI, was defined according to Alfakih 19, 20 with interassay variations <9.8%.
Statistical Analysis
All analyses were performed using SAS software 9.2 (SAS Institute, Cary, NC). The 2-tailed significance level was set at 5%. The sample size allowed to detect a difference ≥0.45 SD between groups with 80% power. The study being exploratory by nature, the overall error rate was not adjusted for multiple testing, and results were appreciated according to their consistency. Between-group comparisons were performed using the nonparametric Mann-Whitney test or the χ 2 test when appropriate. Multivariate linear regressions were performed on LV mass (g, g/m 2 , g/kg, g/height 1.7 , and g/height 2.7
), CRI, PWV, carotid IMT, E′, E′<10 cm/s, and E/E′. Only significant covariables from Table 1 (besides AO, which may be forced) were selected using an interactive backward stepwise method. Intercorrelated variables (eg, SBP, DBP, and MAP) were tested separately in the models. Each biomarker was tested individually in separate models. The conditions of validity of the models (linearity, normality of residuals, homoscedasticity, absence of interaction and colinearity, and impact of outliers) were thoroughly checked for each model. The factors associated with diastolic dysfunction were identified using logistic regression. When the assumption of linearity of the association between diastolic dysfunction and continuous covariable could not be met, the factor was dichotomized according to the Youden and closest to (0,1) criteria. 21 The results are presented as mean±SD, regression coefficient, or odds ratio (95% confidence interval). A confirmatory sensitivity analysis was conducted on a subgroup of 50 patients with AO and 50 controls patients matched on age, sex, and mean BP according to their propensity score, followed by a second analysis restricted to subjects with BP <130/85 mm Hg (optimal or normal BP status according to the 2013 European guidelines of Arterial Hypertension management).
Results
One hundred ninety-two subjects were recruited. Fifty-one (40 AO) were excluded: 41 (29 AO) because of BP >140/90 mm Hg, 4 took antihypertensive therapy, and 6 were on thyroid hormone medication (6 AO). One patient could not attend the second visit. Therefore, our final study population included 140 subjects: 87 subjects in the AO group and 53 controls.
Anthropometric and Metabolic Characteristics
Systolic BP (122±11 versus 116±11 mm Hg; P=0.003) and MAP (89±8 versus 86±7 mm Hg; P=0.022) were significantly higher in subjects with AO (not DBP, 73±8 versus 71±6 mm Hg; P=0.23)-although being still normotensivealong with a higher heart rate (P<0.0001). Leptin concentrations were significantly higher in AO group than in controls (24.8±18.6 versus 7.3±4.8 ng/mL; P<0.0001), and a trend for adiponectin concentrations in AO (3.1±2.3 versus 3.9±2.6; P=0.095; Table 1 ).
Cardiac and Arterial Characteristics
Subjects with AO displayed a LV remodeling as assessed by a significant increase in LV mass (94±24 versus 84±21 g; P=0.034) without reaching LV hypertrophy 17 of procollagen type I concentrations were higher in controls than in AO group (103±49 versus 87±52 ng/mL; P=0.001). In both groups LVEF was normal (P=0.85). In the AO group, E′ was significantly lower and E/E′ higher than that in controls (P<0.0001 and P=0.004, respectively; Table 2 ). Thirty-two patients with AO (38%) had diastolic dysfunction (grade I and II) 11 compared with only 4% of controls. AO subjects with diastolic dysfunction compared with AO without diastolic dysfunction displayed a higher BP (DBP and MAP, P=0.002 and P=0.005, respectively, and a trend for SBP, P=0.077), waist circumference (P=0.028), and CRI (P=0.031; Table S1 in the online-only Data Supplement).
The 2 groups (AO versus controls) did not differ significantly in terms of arterial parameters (ie, PWV [P=0.26] and carotid IMT [P=0.33]). Only 4% of the total population presented significant intima-media thickening (defined as carotid IMT >0.90 mm), and no subject had arterial stiffness as defined by a PWV >12 m/s. 22 There was no association between PWV or IMT on one hand and LV mass (LVM; scaled or not), CRI, and E′ on the other hand.
Structural and Functional Determinants of Cardiac and Arterial Remodeling
In multivariate analysis, SBP (regression coefficient±SEM, 0.33±0.13; P=0.013) and MAP (0.43±0.20; P=0.030) were positively and independently associated with LVM (or scaled LVM as expressed in g/kg of fat-free mass or g/m 1.7 , data not shown) and MAP (0.34±0.16; P=0.035) with CRI. In multivariate analysis, leptin concentrations were significantly associated with LV mass (−0.37±0.12; P=0.003) but not with CRI or diastolic dysfunction. Adiponectin concentrations were not found associated with LV mass, CRI, or diastolic dysfunction. AO was independently associated with CRI (6.26±2.29; P=0.007) and scaled LVM (g/m 1.7 and g/m 2.7 , data not shown) but not with LVM, which was found mainly associated with female sex and body surface area (Table 3) .
In multivariate analysis, diastolic dysfunction was found positively and independently associated with PIIINP concentrations above median (≥2. 4 Finally, considering the higher (although in the normal range) BPs in the AO group, a first sensitivity analysis was performed in a subgroup of 50 patients with AO and 50 control propensity score-matched patients (age, sex, and mean BP). Similar patterns were observed in this subgroup analysis, that is, higher LVM, CRI, and proportion of diastolic dysfunction, with however marginally significant differences (Tables S2 and S3 ). Multivariate analyses confirmed that (1) 
Discussion
Cardiac and Arterial Remodeling: Changes in Structure and Function
The main and novel finding of our study is that in asymptomatic and normotensive healthy subjects with AO, cardiac remodeling (consisting of an increased LV mass) as well as features of cardiac concentric remodeling, which were associated with the AO, and diastolic dysfunction are detectable (the latter associated with increased collagen type III turnover). Importantly, we also examined the possible determinants of such early changes and found that, although in the normal range, BP was strongly associated with indices of cardiac remodeling and diastolic dysfunction in subjects with AO, suggesting a synergistic effect of AO amplifying the deleterious effects of BP.
To analyze the specific effect of AO, we have carefully selected healthy asymptomatic young adult subjects with no hypertension and no known cardiovascular disease. We have also excluded patients with morbid obesity.
Although in elderly patients and patients with hypertension LV hypertrophy, 5 BP, 23 and arterial stiffness 24 are major factors leading to diastolic dysfunction and subsequently to HF with preserved EF, in our AO asymptomatic subjects, we could show that increased LV mass and diastolic dysfunction could be detected early, before LV hypertrophy, hypertension, and arterial stiffening can be diagnosed. Furthermore, increased collagen type III turnover was observed in the study participants with diastolic dysfunction. We also investigated the relationship between LV geometric remodeling, LV function, and markers of myocardial collagen fibrosis indicating cardiac extracellular matrix remodeling. Irrespective of the study group, we were able to identify that collagen type III turnover was positively associated with diastolic dysfunction.
Our finding is novel but consistent with our previous report of increased PIIINP in asymptomatic obese subjects. 7 In such subjects, we had previously reported that PIIINP was independently associated with insulin resistance, 7 which is a common state in AO, and could contribute specifically to increase myocardial fibrosis. Our results further suggest that enhanced collagen type III turnover is associated with early diastolic dysfunction independently from the adipokine pathways (the latter associated with LVM but not with diastolic dysfunction). In our previous report, in obese healthy subjects, 7 PIIINP and E/A ratio were significantly positively correlated. The transformation of the extracellular matrix into a more substantial collagen component potentiated by the increase in LV mass may alter ventricular filling, possibly contributing to the development of LV diastolic dysfunction in subjects with AO. Consistently in patients with hypertension, Martos et al 25 showed that type 1 collagen telopeptide, C-terminal propeptide of procollagen type I, and PIIINP concentrations were higher in patients with symptomatic HF with preserved EF. These findings in various categories of subjects suggest that PIIINP, which predict outcome in HF with preserved EF 26, 27 though not after adjusting for other predictors, 27 could be also a early biomarker of LV diastolic dysfunction.
BP and AO as Therapeutic Targets to Prevent Adverse Cardiac Remodeling?
Subjects with AO had higher SBP and MAP than controls whereas remaining within the normal range and as such not currently eligible for an antihypertensive treatment. Systolic BP and MAP were positively associated with changes in cardiac structure (LV mass, scaled LV mass, and CRI). Furthermore, patients with MAP ≥88 mm Hg had a 4-fold increase in the rate of diastolic dysfunction. Interestingly, BP may be a predominant determinant of structural (LVM and CRI) and functional (diastolic dysfunction) cardiac changes only in high-normal and hypertensive (SBP/DBP ≥ 130/85 mm Hg) subjects with AO but not strictly in normontensive ones.
Although it has already been repeatedly demonstrated that hypertension, via LV hypertrophy and arterial stiffness, leads to diastolic dysfunction, this is the first instance, to our knowledge, demonstrating that BP within the normal range is shown as a determinant of diastolic dysfunction. Some studies highlighted that diastolic dysfunction could be associated with BP in normal range in general population 28 but some were treated for hypertension. 29 Law et al 30 emphasized the key role of BP reduction in everyone to prevent cardiovascular diseases in the setting of the largest meta-analysis of randomized trials on hypertension management. Lowering SBP (by 10 mm Hg) or DBP (by 5 mm Hg) using any of the main classes of BP-lowering drugs reduced cardiovascular events (25% for HF) regardless of BP level before treatment. Furthermore, Julius et al 31 (TROPHY [Trial of Preventing Hypertension] Study) described that subjects at high risk to develop hypertension may benefit from an early intervention to reduce BP by RAAS (renin-angiotensin-aldosterone system) blockers to decrease the risk of incident hypertension and its consequences. In TROPHY Study, subjects were similar to our present study: they were young (48.6±7.9 years old), overweight (body mass index, 29.9±5.1 kg/m 2 ), and most displayed a BP in the high-normal category (SBP, 133.9±4.3 mm Hg; and 23 Furthermore, both angiotensin-converting enzyme inhibitors and angiotensin receptor blocker may decrease the incidence of HF in patients with high cardiovascular risk. [34] [35] [36] [37] We could hypothesize that an aggressive and early management to reduce BP could possibly prevent cardiac structural and functional remodeling in subjects with AO.
Furthermore, that AO was independently associated with the cardiac structural (scaled LVM and CRI) and functional (diastolic dysfunction) remodeling (both in multivariate analyses led within the whole study population and after further adjustment based on propensity-score matching on age, sex, and mean BP in a sensitivity analysis) suggests that lifestyle changes leading to weight loss with reduction in waist circumference, independently from the use of BP-lowering drugs, could be a combination of paramount importance to achieve HF prevention in subjects with AO. Accordingly, in a general population, a waist circumference reduction was found associated with a lower risk to develop hypertension.
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Study Limitations
Our study presents certain limitations. This study is a cross-sectional study, which prohibits from inferring a causative link. Our results may not apply to patients with morbid obesity, which were not included herein. There is no consensus for normalization of LV mass by different types of scaling (height, fat-free mass, body surface area, etc), and parameters used are different according to echocardiography or MRI methods. However, our findings on LV remodeling were consistent throughout the different definitions used for LV mass scaling. BP status of our patients was only analyzed by office BPs although several standardized measurements were performed at each given visit. Furthermore, we previously described thanks to an MRI substudy that there was no difference in aortic PWV between controls and patients with AO. 39 We may hypothesize that arterial changes may not have occurred yet in the subjects we have investigated, who were young and normotensives. Circulating collagen peptides are not specific to cardiac tissue, but previous histological studies observed a significant correlation between collagen peptides serum concentrations and cardiac fibrosis. Circulating collagen peptides are therefore an acceptable surrogate to evaluate cardiac fibrosis turnover. Of note, in the present study, no study participant exhibited abnormal alanine aminotransferase concentrations (data not shown), therefore ruling out the potential confounding effect of nonalcoholic fatty liver disease, which was probably absent in our study population, on PIIINP concentrations. To which extent sleep apnea disorders may have contributed to the observed cardiovascular features was not evaluated herein. Finally, no gadolinium tracer was injected, and thereby myocardial fibrosis could not be assessed in situ.
Perspectives
Normotensive subjects with AO, but otherwise asymptomatic and healthy, exhibit early detectable features of cardiac concentric remodeling as well as of enhanced collagen type III turnover associated with diastolic dysfunction without arterial changes. These alterations may help identifying subjects with AO at higher risk for developing HF with preserved EF and who could potentially benefit from early preventive interventions such as BP lowering, even in normotensive subjects, and weight loss. 
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